Skip to content
Menu

PMV Pharmaceuticals, Inc. PMVP

Full chart Compare
Set alert

Price alert · PMVP

All alert types
1.31 USD +0.09 (+7.38%)

Regular-session close

1.33 +0.02 +1.53%

After hours · Nov 19, 7:58 PM ET

1.23 Day range 1.33
1.02 52-week range 1.91
YTD
+4.80%
1 year
-3.68%

5D +0.05 (+4.00%)

1.101.201.30FriMonTueWedThu1.30
Market cap
98.95M
EPS (ttm)
-1.56
Shares out
51.75M
Forward P/E
-0.96
YTD return
+4.80%
1-year return
-3.68%
50-day average
1.61
200-day average
1.65
Volume
1.20M
Avg volume
702.89K
Open
1.23
Previous close
1.22
Day's range
1.23 – 1.33
52-week range
1.02 – 1.91
Beta
1.48
Price target
5.80 (+342.7%)

Key statistics

Enterprise value
-91.95M
Price / book
0.39
Free cash flow
-39.68M
Total cash
182.84M
Total debt
13.27M
Return on equity
-23.63%
Short % of float
2.01%

Fundamental scorecard

4 of 25 checks passed on PMVP’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PMVP Revenue — quarterly 0
PMVP Net income — quarterly -34.37M
PMVP EPS — quarterly -0.52

Earnings

PMVP recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.35-0.37-0.02-5.71%
Aug 8, 2024Jun 1, 2024-0.34-0.02+0.32+94.12%
Aug 8, 2024Jun 1, 2024-0.34———
May 9, 2024Mar 1, 2024-0.35-0.30+0.05+14.29%
May 9, 2024Mar 1, 2024-0.35———
Feb 29, 2024Dec 1, 2023-0.39———

Upgrades / downgrades

PMVP analyst upgrades and downgrades
DateFirmActionFromTo
Aug 20, 2024HC Wainwright & Co.reitBuyBuy
May 30, 2024HC Wainwright & Co.reitBuyBuy
May 14, 2024HC Wainwright & Co.reitBuyBuy
May 13, 2024Craig-Halluminit—Buy
Apr 12, 2024Jefferiesinit—Buy
Mar 7, 2024HC Wainwright & Co.reitBuyBuy

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on PMVP — it syncs with the Stock Master app.

Insider holders

PMVP insider holders
InsiderRelationLatest transactionDateShares held
ALLAND LEILAOfficerSaleSep 14, 202345,909
CARULLI MICHAELChief Financial OfficerSaleSep 10, 202488,395
JALOTA DEEPIKAOfficerSaleSep 10, 2024118,283
MACK DAVID HENRYChief Executive OfficerStock Award(Grant)Jan 17, 2024812,660
ORBIMED ADVISORS, L.L.C.Beneficial Owner of more than 10% of a Class of SecuritySaleNov 21, 20230

Institution ownership

PMVP institution ownership
Holder% heldSharesValueReported
Orbimed Advisors LLC.12.51%6,475,2919.78MSep 29, 2024
ArrowMark Colorado Holdings LLC7.05%3,647,2915.51MSep 29, 2024
Sio Capital Management, LLC6.21%3,214,2394.85MSep 29, 2024
Euclidean Capital Llc5.08%2,627,6433.97MSep 29, 2024
Alkeon Capital Management LLC4.53%2,343,7313.54MSep 29, 2024
Vanguard Group Inc4.41%2,280,8033.44MSep 29, 2024

Fund ownership

PMVP fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.95%1,524,4872.30MSep 29, 2024
Meridian Small Cap Growth Fund2.43%1,255,4731.90MSep 29, 2024
ACAP Strategic Fund2.22%1,147,0951.73MSep 29, 2024
Vanguard Extended Market Index Fund1.04%540,351815.93KSep 29, 2024
Advantage Advisers Xanthus Fund, LLC0.64%329,949498.22KSep 29, 2024
BlackRock Advantage Small Cap Core Fund0.54%280,445423.47KAug 30, 2024